Suppr超能文献

原发性中枢神经系统淋巴瘤:跨区间进展。

Primary central nervous system lymphoma: Inter-compartmental progression.

作者信息

Raval Vishal, Binkley Elaine, Aronow Mary E, Valenzuela Juan, Peereboom David M, Wei Wei, Srivastava Sunil, Davanzo Jaqueline, Boldt Herbert Culver, McGarrey Mark P, Papaliodis George N, Sobrin Lucia, Kim Ivana K, Vavvas Dimitrios G, Eliott Dean, Nayak Lakshmi, Dodds Emilio, Marco Del Pont Francisco, Singh Arun D

机构信息

Department of Ophthalmic Oncology Cole Eye Institute Cleveland Clinic Cleveland Ohio USA.

Department of Ophthalmology and Visual Sciences University of Iowa Iowa City Iowa USA.

出版信息

EJHaem. 2022 Jan 20;3(2):362-370. doi: 10.1002/jha2.303. eCollection 2022 May.

Abstract

There is limited understanding of the inter-compartmental progression and treatment outcomes of primary central nervous system lymphoma (PCNSL). In this multicenter retrospective cohort study on 234 patients with PCNSL (median age: 62.5 years [18-92]; median follow-up 35 months [0.1-237.0]) from 2000 till 2018 were divided into group 1 (ocular, 44 patients): 1A and 1B without and with CNS progression and group 2 (CNS, 190 patients): 2A and 2B without and with ocular progression, respectively. In group 1 (44 patients), 33 patients received local treatment, and 11 patients received systemic treatment. In group 2 (15 patients), six patients received combination treatment, while seven patients received only systemic treatment. A complete response was observed in 19 (43%) and 91 (48%) patients in groups 1 and 2, respectively. The 2-year progression-free survival (PFS) was 35% (95% CI: 0.23, 0.54) and 56% (95% CI: 0.49, 0.63) for groups 1 and 2, respectively ( < 0.0001). Age < 60 years was significantly associated with longer PFS (median PFS 48 vs. 24 months,  = 0.01). The overall survival (OS) at 2-year was similar among groups 1 and 2 (83% and 67%), respectively ( = 0.06). Thus, Initial compartment of involvement does not influence local response rate or OS.

摘要

目前对原发性中枢神经系统淋巴瘤(PCNSL)的不同部位进展情况和治疗结果了解有限。在这项多中心回顾性队列研究中,2000年至2018年间的234例PCNSL患者(中位年龄:62.5岁[18 - 92岁];中位随访时间35个月[0.1 - 237.0个月])被分为1组(眼部,44例患者):1A组和1B组分别为无中枢神经系统进展和有中枢神经系统进展的患者;以及2组(中枢神经系统,190例患者):2A组和2B组分别为无眼部进展和有眼部进展的患者。在1组(44例患者)中,33例患者接受了局部治疗,11例患者接受了全身治疗。在2组(15例患者)中,6例患者接受了联合治疗,7例患者仅接受了全身治疗。1组和2组分别有19例(43%)和91例(48%)患者观察到完全缓解。1组和2组的2年无进展生存期(PFS)分别为35%(95%CI:0.23,0.54)和56%(95%CI:0.49,0.63)(P < 0.0001)。年龄<60岁与更长的PFS显著相关(中位PFS为48个月对24个月,P = 0.01)。1组和2组的2年总生存期(OS)相似,分别为83%和67%(P = 0.06)。因此,初始受累部位不影响局部缓解率或总生存期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b31/9175875/d473f9995ac4/JHA2-3-362-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验